Verónica González-Calle, Marcos González, Marta Rodríguez, Alicia Antón, M. Dolores Caballero, M. Eugenia Sarasquete, Alejandro Medina, María García-Álvarez, M. Carmen Chillón, Ana Balanzategui, Sara Alonso-Álvarez, Noemi Puig, Cristina Jiménez, Isabel Prieto-Conde, Pilar Tamayo, Alejandro Martín, Rebeca Maldonado, Ramón García-Sanz, Oscar Blanco, Miguel Alcoceba, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad (España), Junta de Castilla y León, Sociedad Española de Hematología y Hemoterapia, Fundación CRIS contra el Cáncer, and European Commission
© The Author(s) 2019., Follicular lymphoma (FL) is a heterogeneous disease whose pathogenesis remains partially unknown. Around 20% of FL patients experience early progression or treatment-refractory disease and 2–3% of patients per year experience histological transformation (HT) into a more aggressive lymphoma (tFL). Here, we evaluate the immunoglobulin heavy chain variable (IGHV) gene usage and mutational status in 187 FL cases to assess its impact on clinical outcome and histological transformation. The IGHV gene repertoire was remarkably biased in FL. The IGHV4-34 (14%), IGHV3-23 (14%), IGHV3-48 (10%), IGHV3-30 (9%) and IGHV3-21 (7%) genes accounted for more than half of the whole cohort. IGHV3-48 was overrepresented in cases of tFL (19%) compared with non-transformed FL at 5 years (5%, P = 0.05). Patients with the IGHV3-48 gene were significantly more likely to have had HT after 10 years than those who used other genes (71% vs. 25%, P, This work was partially supported by the Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Economy and Competitiveness PI15/01393, PI18-00410, RD12/0036/0069, CIBERONC-CB16/12/00233, and “Una manera de hacer Europa” (Innocampus; CEI-2010-1-0010)”, the Education Council or Health Council of the Junta de Castilla y León (CAS102P17, GRS 1180/A/15), and Gilead Sciences (GLD17/00334). M.G.A., I.P.C. and C.J. are supported by the Fundación Española de Hematología y Hemoterapia (FEHH, co-funded by Fundación Cris in the latter case), and M.E.S. by the ISCIII (CPII18/00028). All Spanish funding is co-sponsored by the European Union FEDER program.